Genprex Faces Nasdaq Delisting Risk Over Compliance Shortfalls
Genprex Inc. faces potential delisting from Nasdaq due to non-compliance with the $1.00 minimum bid price and minimum stockholders’ equity requirements. The company has until October 31, 2025, to meet these criteria. Genprex may need to raise additional capital, but there is no guarantee of securing sufficient financing. Failure to comply could result in delisting.
Genprex Inc. is facing regulatory challenges related to its continued listing on the Nasdaq Capital Market. The company has been notified by the Nasdaq Hearings Panel that it has until October 31, 2025, to regain compliance with the $1.00 minimum bid price requirement and the minimum stockholders’ equity requirement as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). Genprex has indicated that it may need to raise additional capital to meet these requirements, but there is no assurance that such financing will be available or sufficient to resolve the deficiencies. Failure to comply with these rules could result in the delisting of Genprex’s common stock from Nasdaq. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-036380), on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
